Evidence map›Paper›PMID 41649705›Full record

ReviewDiscover nano2026

Nanoparticle approaches for hepatitis therapy and clinical translation.

Nura Adam Mohamed, Farah Atifi, Zineb Ourradi, Sergio Crovella, Moutaz Derbala, Hadi M Yassine, Ejaife O Agbani, Yahye Merhi, Younes Zaid, Haissam Abou-Saleh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nura Adam MohamedMedical and Health Sciences Office, QU-Health, Qatar University, Doha, Qatar.
Farah AtifiMaterials, Nanotechnologies and Environment Laboratory, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco.
Zineb OurradiMaterials, Nanotechnologies and Environment Laboratory, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco.
Sergio CrovellaBiomedical Sciences Department, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
Moutaz DerbalaGastroenterology and Hepatology Department, Hamad Medical Corporation, Doha, Qatar.
Hadi M YassineBiomedical Research Center, QU Health, Qatar University, Doha, Qatar.
Ejaife O AgbaniDepartment of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Yahye MerhiLaboratory of Thrombosis and Hemostasis, Research Center, Montreal Heart Institute, Faculty of Medicine, Université de Montréal, Montreal, QC, H3T 1J4, Canada.
Younes ZaidMaterials, Nanotechnologies and Environment Laboratory, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco.
Haissam Abou-SalehMedical and Health Sciences Office, QU-Health, Qatar University, Doha, Qatar. hasaleh@qu.edu.qa.

Funding

Qatar University IRCC-738
6 · The paper itself

Abstract

backgroundHepatitis B and C viruses (HBV and HCV) remain major global health challenges, contributing significantly to liver-related morbidity and mortality worldwide. Although direct-acting antivirals (DAAs) have improved patient outcomes, key limitations persist, including suboptimal hepatic targeting, emerging drug resistance, incomplete viral eradication, and systemic side effects. AREA COVERED: Nanotechnology offers a promising avenue for enhancing and personalizing antiviral treatments. This review explores recent advances in nanoparticle (NP)-based strategies for HBV and HCV therapy, focusing on design principles, delivery platforms, and translational applications. Lipid-based, polymeric, metallic/inorganic, and biomimetic nanocarriers are examined for drug delivery, gene editing, and vaccine development. Targeted strategies-such as galactose-mediated hepatic uptake and pH-responsive release-demonstrate the potential to improve drug localization and reduce off-target toxicity. Preclinical studies, including siRNA-loaded lipid nanoparticles, have shown significant antiviral effects in animal models. In addition, emerging AI-driven frameworks for nanoparticle design and prediction are highlighted as tools that may accelerate optimization and therapeutic personalization. Despite these advances, translation into clinical practice remains limited due to challenges such as immunogenicity, systemic instability, manufacturing scalability, and regulatory complexity. EXPERT OPINION: To facilitate clinical translation, a clear developmental roadmap is needed that emphasizes interdisciplinary collaboration, standardized safety evaluations, and patient-centered treatment strategies. Continued innovation-including integration of nanotechnology with artificial intelligence, gene-editing approaches, and immunomodulatory platforms-holds strong potential to transform HBV and HCV management and enable safer, more effective therapeutic options beyond current antiviral approaches.

Indexed as

CRISPR/Cas9 deliveryHepatic targetingHepatitis B and CNanoparticle drug deliveryNano-vaccines

Identifiers

PMID41649705
PMCPMC12881238

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.